Actively Recruiting
Phase II Study of BL-B01D1 Injection for Treating Recurrent Glioblastoma in Adults
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2025-05-07
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, effectiveness, and how the body processes BL-B01D1 for Injection in adults with recurrent glioblastoma, a type of brain cancer that has returned after standard treatment. This open-label, phase II study is being conducted at multiple centers and aims to provide important information about this treatment option for patients with this challenging condition. Participants receive BL-B01D1 through an intravenous infusion over a cycle lasting three weeks. Those who show clinical benefit may continue receiving additional treatment cycles. Treatment will stop if the disease progresses, intolerable side effects occur, or for other reasons determined by the study team. During the study, participants will be closely monitored for their response to treatment, including tumor response and disease control, as well as any side effects. Researchers will also assess how the drug moves through the body by measuring levels in the blood over approximately 24 months. Participants will undergo regular evaluations to track their progress and safety throughout the study period.
CONDITIONS
Brief Title
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
